Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Healthequity (HQY) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Healthequity (HQY) over the last 13 years, with Q4 2025 value amounting to $309.3 million.

  • Healthequity's Cash & Equivalents fell 400.54% to $309.3 million in Q4 2025 from the same period last year, while for Oct 2025 it was $309.3 million, marking a year-over-year decrease of 400.54%. This contributed to the annual value of $295.9 million for FY2025, which is 2674.17% down from last year.
  • Latest data reveals that Healthequity reported Cash & Equivalents of $309.3 million as of Q4 2025, which was down 400.54% from $304.5 million recorded in Q3 2025.
  • In the past 5 years, Healthequity's Cash & Equivalents registered a high of $753.8 million during Q3 2021, and its lowest value of $161.2 million during Q2 2022.
  • Moreover, its 5-year median value for Cash & Equivalents was $300.2 million (2025), whereas its average is $342.4 million.
  • As far as peak fluctuations go, Healthequity's Cash & Equivalents soared by 33062.72% in 2021, and later plummeted by 7811.44% in 2022.
  • Quarter analysis of 5 years shows Healthequity's Cash & Equivalents stood at $649.1 million in 2021, then plummeted by 67.62% to $210.2 million in 2022, then skyrocketed by 58.93% to $334.1 million in 2023, then fell by 3.56% to $322.2 million in 2024, then decreased by 4.01% to $309.3 million in 2025.
  • Its Cash & Equivalents was $309.3 million in Q4 2025, compared to $304.5 million in Q3 2025 and $287.9 million in Q2 2025.